207 related articles for article (PubMed ID: 22351432)
1. 5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity.
Burnett BP; Levy RM
Adv Ther; 2012 Feb; 29(2):79-98. PubMed ID: 22351432
[TBL] [Abstract][Full Text] [Related]
2. Safety of anti-inflammatory treatment--new ways of thinking.
Brune K
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i16-20. PubMed ID: 14752171
[TBL] [Abstract][Full Text] [Related]
3. Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept.
Gaddi A; Cicero AF; Pedro EJ
Arch Gerontol Geriatr; 2004; 38(3):201-12. PubMed ID: 15066307
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?
Fiorucci S; Meli R; Bucci M; Cirino G
Biochem Pharmacol; 2001 Dec; 62(11):1433-8. PubMed ID: 11728379
[TBL] [Abstract][Full Text] [Related]
5. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.
Hong SH; Avis I; Vos MD; Martínez A; Treston AM; Mulshine JL
Cancer Res; 1999 May; 59(9):2223-8. PubMed ID: 10232612
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids.
Martel-Pelletier J; Mineau F; Fahmi H; Laufer S; Reboul P; Boileau C; Lavigne M; Pelletier JP
Arthritis Rheum; 2004 Dec; 50(12):3925-33. PubMed ID: 15593193
[TBL] [Abstract][Full Text] [Related]
7. Using the medical food flavocoxid [corrected] in managing osteoarthritis.
Gottlieb D; Kuritzky L
J Pain Palliat Care Pharmacother; 2011; 25(1):49-54. PubMed ID: 21426218
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory potential of 2-styrylchromones regarding their interference with arachidonic acid metabolic pathways.
Gomes A; Fernandes E; Silva AM; Pinto DC; Santos CM; Cavaleiro JA; Lima JL
Biochem Pharmacol; 2009 Jul; 78(2):171-7. PubMed ID: 19464432
[TBL] [Abstract][Full Text] [Related]
9. COX-LOX inhibition: current evidence for an emerging new therapy.
Skelly MM; Hawkey CJ
Int J Clin Pract; 2003 May; 57(4):301-4. PubMed ID: 12800462
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells.
Ferrera P; Arias C
Neurochem Int; 2005 Dec; 47(8):589-96. PubMed ID: 16169124
[TBL] [Abstract][Full Text] [Related]
11. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells.
Shureiqi I; Chen D; Lotan R; Yang P; Newman RA; Fischer SM; Lippman SM
Cancer Res; 2000 Dec; 60(24):6846-50. PubMed ID: 11156377
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system.
Fosslien E
Ann Clin Lab Sci; 1998; 28(2):67-81. PubMed ID: 9558445
[TBL] [Abstract][Full Text] [Related]
13. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade.
Tavolari S; Bonafè M; Marini M; Ferreri C; Bartolini G; Brighenti E; Manara S; Tomasi V; Laufer S; Guarnieri T
Carcinogenesis; 2008 Feb; 29(2):371-80. PubMed ID: 18033773
[TBL] [Abstract][Full Text] [Related]
14. Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues.
Zheng M; Zhang Z; Zhu W; Liu H; Luo X; Chen K; Jiang H
Bioorg Med Chem; 2006 May; 14(10):3428-37. PubMed ID: 16458008
[TBL] [Abstract][Full Text] [Related]
15. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
16. Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
Alvaro-Gracia JM
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i21-5. PubMed ID: 14752172
[TBL] [Abstract][Full Text] [Related]
17. An update on eicosanoids and inhibitors of cyclooxygenase enzyme systems.
Sharma S; Sharma SC
Indian J Exp Biol; 1997 Oct; 35(10):1025-31. PubMed ID: 9475035
[TBL] [Abstract][Full Text] [Related]
18. Dual acting anti-inflammatory drugs.
Leone S; Ottani A; Bertolini A
Curr Top Med Chem; 2007; 7(3):265-75. PubMed ID: 17305569
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of aspirin sensitivity.
Picado C
Curr Allergy Asthma Rep; 2006 May; 6(3):198-202. PubMed ID: 16579869
[TBL] [Abstract][Full Text] [Related]
20. Synthetically-tailored and nature-derived dual COX-2/5-LOX inhibitors: Structural aspects and SAR.
Meshram MA; Bhise UO; Makhal PN; Kaki VR
Eur J Med Chem; 2021 Dec; 225():113804. PubMed ID: 34479036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
